Skip to main content
Erschienen in: Calcified Tissue International 2/2018

14.11.2017 | Review

Hallmarks of Bone Metastasis

verfasst von: Rachelle W. Johnson, Larry J. Suva

Erschienen in: Calcified Tissue International | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer bone metastasis develops as the result of a series of complex interactions between tumor cells, bone marrow cells, and resident bone cells. The net effect of these interactions are the disruption of normal bone homeostasis, often with significantly increased osteoclast and osteoblast activity, which has provided a rational target for controlling tumor progression, with little or no emphasis on tumor eradication. Indeed, the clinical course of metastatic breast cancer is relatively long, with patients likely to experience sequential skeletal-related events (SREs), often over lengthy periods of time, even up to decades. These SREs include bone pain, fractures, and spinal cord compression, all of which may profoundly impair a patient’s quality-of-life. Our understanding of the contributions of the host bone and bone marrow cells to the control of tumor progression has grown over the years, yet the focus of virtually all available treatments remains on the control of resident bone cells, primarily osteoclasts. In this perspective, our focus is to move away from the current emphasis on the control of bone cells and focus our attention on the hallmarks of bone metastatic tumor cells and how these differ from primary tumor cells and normal host cells. In our opinion, there remains a largely unmet medical need to develop and utilize therapies that impede metastatic tumor cells while sparing normal host bone and bone marrow cells. This perspective examines the impact of metastatic tumor cells on the bone microenvironment and proposes potential new directions for uncovering the important mechanisms driving metastatic progression in bone based on the hallmarks of bone metastasis.
Literatur
1.
Zurück zum Zitat Suva LJ, Gaddy D, Perrien DS, Thomas RL, Findlay DM (2005) Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep 3:46–51PubMedCrossRef Suva LJ, Gaddy D, Perrien DS, Thomas RL, Findlay DM (2005) Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep 3:46–51PubMedCrossRef
2.
Zurück zum Zitat Reagan MR, Rosen CJ (2016) Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol 12:154–168PubMedCrossRef Reagan MR, Rosen CJ (2016) Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol 12:154–168PubMedCrossRef
6.
Zurück zum Zitat Zhou HS, Carter BZ, Andreeff M (2016) Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med 13:248–259PubMedPubMedCentralCrossRef Zhou HS, Carter BZ, Andreeff M (2016) Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med 13:248–259PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Makhoul I, Montgomery CO, Gaddy D, Suva LJ (2016) The best of both worlds—managing the cancer, saving the bone. Nat Rev Endocrinol 12:29–42PubMedCrossRef Makhoul I, Montgomery CO, Gaddy D, Suva LJ (2016) The best of both worlds—managing the cancer, saving the bone. Nat Rev Endocrinol 12:29–42PubMedCrossRef
9.
Zurück zum Zitat Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef
10.
Zurück zum Zitat Guise TA et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544–1549PubMedPubMedCentralCrossRef Guise TA et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544–1549PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Suva LJ et al (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896PubMedCrossRef Suva LJ et al (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896PubMedCrossRef
12.
Zurück zum Zitat Mundy GR, Edwards JR (2008) PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 19:672–675PubMedCrossRef Mundy GR, Edwards JR (2008) PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 19:672–675PubMedCrossRef
14.
15.
Zurück zum Zitat Coleman RE et al (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol 2:70–76PubMedPubMedCentralCrossRef Coleman RE et al (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol 2:70–76PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRef Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRef
17.
Zurück zum Zitat Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339–351PubMedCrossRef Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339–351PubMedCrossRef
18.
19.
Zurück zum Zitat Pantel K, Riethdorf S (2009) Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol 6:190–191PubMedCrossRef Pantel K, Riethdorf S (2009) Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol 6:190–191PubMedCrossRef
20.
Zurück zum Zitat Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312PubMedCrossRef Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312PubMedCrossRef
21.
Zurück zum Zitat Price TT et al (2016) Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med 8:340ra373CrossRef Price TT et al (2016) Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med 8:340ra373CrossRef
22.
Zurück zum Zitat Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK (2013) Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19:6389–6397PubMedCrossRef Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK (2013) Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19:6389–6397PubMedCrossRef
23.
Zurück zum Zitat Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 16:373–386PubMedCrossRef Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 16:373–386PubMedCrossRef
24.
Zurück zum Zitat Alvarez-Cubero MJ et al (2016) Dormant circulating tumor cells in prostate cancer: therapeutic, clinical and biological implications. Curr Drug Targets 17:693–701PubMedCrossRef Alvarez-Cubero MJ et al (2016) Dormant circulating tumor cells in prostate cancer: therapeutic, clinical and biological implications. Curr Drug Targets 17:693–701PubMedCrossRef
25.
26.
Zurück zum Zitat Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J (2006) C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10:203–214PubMedCrossRef Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J (2006) C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10:203–214PubMedCrossRef
27.
Zurück zum Zitat Tomasetti C, Vogelstein B (2015) Cancer risk: role of environment-response. Science 347:729–731PubMedCrossRef Tomasetti C, Vogelstein B (2015) Cancer risk: role of environment-response. Science 347:729–731PubMedCrossRef
28.
Zurück zum Zitat Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91:411–429CrossRef Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91:411–429CrossRef
30.
Zurück zum Zitat Giuliano AE et al (2011) Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385–393PubMedPubMedCentralCrossRef Giuliano AE et al (2011) Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385–393PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Giuliano AE et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432 discussion 432–423 PubMedPubMedCentral Giuliano AE et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432 discussion 432–423 PubMedPubMedCentral
32.
Zurück zum Zitat Viehl CT et al (2011) Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. J Surg Oncol 103:531–533PubMedCrossRef Viehl CT et al (2011) Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. J Surg Oncol 103:531–533PubMedCrossRef
33.
Zurück zum Zitat Karpanen T et al (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786–1790PubMed Karpanen T et al (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786–1790PubMed
34.
Zurück zum Zitat Thomas R et al (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451–4458PubMedCrossRef Thomas R et al (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451–4458PubMedCrossRef
35.
Zurück zum Zitat Johnson RW et al (2016) Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol 18:1078–1089PubMedPubMedCentralCrossRef Johnson RW et al (2016) Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol 18:1078–1089PubMedPubMedCentralCrossRef
36.
37.
Zurück zum Zitat Hoar FJ, Chaudhri S, Wadley MS, Stonelake PS (2003) Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur J Cancer 39:1698–1703PubMedCrossRef Hoar FJ, Chaudhri S, Wadley MS, Stonelake PS (2003) Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur J Cancer 39:1698–1703PubMedCrossRef
38.
Zurück zum Zitat Park HR, Min K, Kim HS, Jung WW, Park YK (2008) Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. Pathol Res Pract 204:575–582PubMedCrossRef Park HR, Min K, Kim HS, Jung WW, Park YK (2008) Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. Pathol Res Pract 204:575–582PubMedCrossRef
39.
Zurück zum Zitat Tzeng HE, Chang AC, Tsai CH, Wang SW, Tang CH (2016) Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells. Oncotarget 7:38566–38578PubMedPubMedCentralCrossRef Tzeng HE, Chang AC, Tsai CH, Wang SW, Tang CH (2016) Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells. Oncotarget 7:38566–38578PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Huang CY et al (2016) Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells. Clin Sci (Lond) 130:1523–1533CrossRef Huang CY et al (2016) Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells. Clin Sci (Lond) 130:1523–1533CrossRef
41.
Zurück zum Zitat Yang WH et al (2016) Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. Sci Rep 6:28647PubMedPubMedCentralCrossRef Yang WH et al (2016) Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. Sci Rep 6:28647PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Paszek MJ, Weaver VM (2004) The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 9:325–342PubMedCrossRef Paszek MJ, Weaver VM (2004) The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 9:325–342PubMedCrossRef
44.
Zurück zum Zitat Kwakwa KA, Sterling JA (2017) Integrin alphavbeta3 signaling in tumor-induced bone disease. Cancers (Basel) 9:84CrossRef Kwakwa KA, Sterling JA (2017) Integrin alphavbeta3 signaling in tumor-induced bone disease. Cancers (Basel) 9:84CrossRef
45.
Zurück zum Zitat Kwakwa KA, Vanderburgh JP, Guelcher SA, Sterling JA (2017) Engineering 3D models of tumors and bone to understand tumor-induced bone disease and improve treatments. Curr Osteoporos Rep 15:247–254PubMedCrossRef Kwakwa KA, Vanderburgh JP, Guelcher SA, Sterling JA (2017) Engineering 3D models of tumors and bone to understand tumor-induced bone disease and improve treatments. Curr Osteoporos Rep 15:247–254PubMedCrossRef
47.
Zurück zum Zitat Johnson RW et al (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945–959PubMedPubMedCentralCrossRef Johnson RW et al (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945–959PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Page JM et al (2015) Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II. Biomaterials 64:33–44PubMedPubMedCentralCrossRef Page JM et al (2015) Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II. Biomaterials 64:33–44PubMedPubMedCentralCrossRef
49.
50.
Zurück zum Zitat Johnson RW, Sowder ME, Giaccia AJ (2017) Hypoxia and bone metastatic disease. Curr Osteoporos Rep 15:231–238PubMedCrossRef Johnson RW, Sowder ME, Giaccia AJ (2017) Hypoxia and bone metastatic disease. Curr Osteoporos Rep 15:231–238PubMedCrossRef
52.
Zurück zum Zitat Chow DC, Wenning LA, Miller WM, Papoutsakis ET (2001) Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 81:685–696PubMedPubMedCentralCrossRef Chow DC, Wenning LA, Miller WM, Papoutsakis ET (2001) Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 81:685–696PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Harrison JS, Rameshwar P, Chang V, Bandari P (2002) Oxygen saturation in the bone marrow of healthy volunteers. Blood 99:394PubMedCrossRef Harrison JS, Rameshwar P, Chang V, Bandari P (2002) Oxygen saturation in the bone marrow of healthy volunteers. Blood 99:394PubMedCrossRef
54.
Zurück zum Zitat Bendre MS et al (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571–5579PubMed Bendre MS et al (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571–5579PubMed
55.
Zurück zum Zitat Chou SC, Azuma Y, Varia MA, Raleigh JA (2004) Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 90:728–735PubMedPubMedCentralCrossRef Chou SC, Azuma Y, Varia MA, Raleigh JA (2004) Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 90:728–735PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W (1995) Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 61:567–573PubMedCrossRef Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W (1995) Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 61:567–573PubMedCrossRef
57.
Zurück zum Zitat Dupuy F et al (2015) PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab 22:577–589PubMedCrossRef Dupuy F et al (2015) PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab 22:577–589PubMedCrossRef
58.
Zurück zum Zitat Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593PubMedCrossRef Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593PubMedCrossRef
59.
61.
Zurück zum Zitat Junankar S et al (2015) Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 5:35–42PubMedCrossRef Junankar S et al (2015) Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 5:35–42PubMedCrossRef
63.
65.
Zurück zum Zitat Lau YS et al (2007) RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Res Treat 105:7–16PubMedCrossRef Lau YS et al (2007) RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Res Treat 105:7–16PubMedCrossRef
66.
Zurück zum Zitat Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef
67.
Zurück zum Zitat Fournier PG, Chirgwin JM, Guise TA (2006) New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18:396–404PubMedCrossRef Fournier PG, Chirgwin JM, Guise TA (2006) New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18:396–404PubMedCrossRef
68.
Zurück zum Zitat Kamalakar A et al (2017) PTHrP(12-48) modulates the bone marrow microenvironment and suppresses human osteoclast differentiation and lifespan. J Bone Miner Res 32:1421–1431PubMedPubMedCentralCrossRef Kamalakar A et al (2017) PTHrP(12-48) modulates the bone marrow microenvironment and suppresses human osteoclast differentiation and lifespan. J Bone Miner Res 32:1421–1431PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Palumbo C, Ferretti M, Marotti G (2004) Osteocyte dendrogenesis in static and dynamic bone formation: an ultrastructural study. Anat Rec A 278:474–480CrossRef Palumbo C, Ferretti M, Marotti G (2004) Osteocyte dendrogenesis in static and dynamic bone formation: an ultrastructural study. Anat Rec A 278:474–480CrossRef
72.
Zurück zum Zitat Nakashima T et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231–1234PubMedCrossRef Nakashima T et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231–1234PubMedCrossRef
74.
Zurück zum Zitat Giuliani N et al (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26:1391–1401PubMedCrossRef Giuliani N et al (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26:1391–1401PubMedCrossRef
75.
76.
Zurück zum Zitat Gkotzamanidou M et al (2012) Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets 16:761–769PubMedCrossRef Gkotzamanidou M et al (2012) Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets 16:761–769PubMedCrossRef
77.
Zurück zum Zitat Mendoza-Villanueva D, Zeef L, Shore P (2011) Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 13:R106PubMedPubMedCentralCrossRef Mendoza-Villanueva D, Zeef L, Shore P (2011) Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 13:R106PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Wilson C, Coleman R (2016) Adjuvant bone-targeted therapies for postmenopausal breast cancer. JAMA Oncol 2:423–424PubMedCrossRef Wilson C, Coleman R (2016) Adjuvant bone-targeted therapies for postmenopausal breast cancer. JAMA Oncol 2:423–424PubMedCrossRef
79.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353–1361CrossRef Early Breast Cancer Trialists’ Collaborative Group (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353–1361CrossRef
80.
Zurück zum Zitat Taipaleenmaki H et al (2016) Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget 7:79032–79046PubMedPubMedCentralCrossRef Taipaleenmaki H et al (2016) Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget 7:79032–79046PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Hassan MQ et al (2012) miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 287:42084–42092PubMedPubMedCentralCrossRef Hassan MQ et al (2012) miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 287:42084–42092PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Yin JJ et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206PubMedPubMedCentralCrossRef Yin JJ et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Biswas S et al (2011) Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE 6:e27090PubMedPubMedCentralCrossRef Biswas S et al (2011) Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE 6:e27090PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Johnson RW et al (2011) TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 71:822–831PubMedCrossRef Johnson RW et al (2011) TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 71:822–831PubMedCrossRef
85.
Zurück zum Zitat Sterling JA et al (2006) The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66:7548–7553PubMedCrossRef Sterling JA et al (2006) The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66:7548–7553PubMedCrossRef
86.
Zurück zum Zitat Heller E et al (2012) Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 72:897–907PubMedCrossRef Heller E et al (2012) Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 72:897–907PubMedCrossRef
87.
Zurück zum Zitat Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411:349–354PubMedCrossRef Taipale J, Beachy PA (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature 411:349–354PubMedCrossRef
88.
Zurück zum Zitat Mohammad KS et al (2011) TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 71:175–184PubMedCrossRef Mohammad KS et al (2011) TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 71:175–184PubMedCrossRef
89.
Zurück zum Zitat Cannonier SA, Gonzales CB, Ely K, Guelcher SA, Sterling JA (2016) Hedgehog and TGFbeta signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. Oncotarget 7:76062–76075PubMedPubMedCentralCrossRef Cannonier SA, Gonzales CB, Ely K, Guelcher SA, Sterling JA (2016) Hedgehog and TGFbeta signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. Oncotarget 7:76062–76075PubMedPubMedCentralCrossRef
91.
Zurück zum Zitat Bendre MS et al (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28–37PubMedCrossRef Bendre MS et al (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28–37PubMedCrossRef
92.
Zurück zum Zitat Zheng Y et al (2014) Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis 31:921–933PubMedCrossRef Zheng Y et al (2014) Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis 31:921–933PubMedCrossRef
93.
Zurück zum Zitat Luo X et al (2016) Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep 14:82–92PubMedCrossRef Luo X et al (2016) Stromal-initiated changes in the bone promote metastatic niche development. Cell Rep 14:82–92PubMedCrossRef
94.
Zurück zum Zitat Williams SC (2013) First IL-6-blocking drug nears approval for rare blood disorder. Nat Med 19:1193PubMedCrossRef Williams SC (2013) First IL-6-blocking drug nears approval for rare blood disorder. Nat Med 19:1193PubMedCrossRef
95.
Zurück zum Zitat Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1414PubMedCentralCrossRef Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1414PubMedCentralCrossRef
96.
Zurück zum Zitat Pratap J et al (2010) The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9:3210–3220PubMedPubMedCentralCrossRef Pratap J et al (2010) The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9:3210–3220PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Larson SR et al (2014) Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis 31:247–256PubMedCrossRef Larson SR et al (2014) Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis 31:247–256PubMedCrossRef
99.
Zurück zum Zitat Suva LJ, Brander BE, Makhoul I (2011) Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol 7:380–381PubMedCrossRef Suva LJ, Brander BE, Makhoul I (2011) Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol 7:380–381PubMedCrossRef
100.
Zurück zum Zitat Kelly T et al (2005) Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778–5784PubMedCrossRef Kelly T et al (2005) Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778–5784PubMedCrossRef
101.
Zurück zum Zitat Ozdemir BC et al (2014) The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS ONE 9:e114530PubMedPubMedCentralCrossRef Ozdemir BC et al (2014) The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS ONE 9:e114530PubMedPubMedCentralCrossRef
104.
Zurück zum Zitat Vilalta M, Rafat M, Giaccia AJ, Graves EE (2014) Recruitment of circulating breast cancer cells is stimulated by radiotherapy. Cell Rep 8:402–409PubMedPubMedCentralCrossRef Vilalta M, Rafat M, Giaccia AJ, Graves EE (2014) Recruitment of circulating breast cancer cells is stimulated by radiotherapy. Cell Rep 8:402–409PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Manolagas S (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMed Manolagas S (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMed
106.
Zurück zum Zitat Martinez LM et al (2014) Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis 31:213–232PubMedCrossRef Martinez LM et al (2014) Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis 31:213–232PubMedCrossRef
107.
Zurück zum Zitat Stine KC et al (2014) Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res 32:464–470PubMedCrossRef Stine KC et al (2014) Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res 32:464–470PubMedCrossRef
108.
Zurück zum Zitat Stine KC et al (2016) Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res 34:1716–1724PubMedPubMedCentralCrossRef Stine KC et al (2016) Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res 34:1716–1724PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat Xiong J et al (2015) Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS ONE 10:e0138189PubMedPubMedCentralCrossRef Xiong J et al (2015) Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS ONE 10:e0138189PubMedPubMedCentralCrossRef
110.
Zurück zum Zitat Bultynck G (2016) The anti-metastatic micro-environment of the bone: importance of osteocyte Cx43 hemichannels. Biochim Biophys Acta 1866:121–127PubMed Bultynck G (2016) The anti-metastatic micro-environment of the bone: importance of osteocyte Cx43 hemichannels. Biochim Biophys Acta 1866:121–127PubMed
112.
Zurück zum Zitat Giustacchini A et al (2017) Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 23:692–702PubMedCrossRef Giustacchini A et al (2017) Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 23:692–702PubMedCrossRef
Metadaten
Titel
Hallmarks of Bone Metastasis
verfasst von
Rachelle W. Johnson
Larry J. Suva
Publikationsdatum
14.11.2017
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 2/2018
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-017-0362-4

Weitere Artikel der Ausgabe 2/2018

Calcified Tissue International 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.